Glanbia shares tumble 6% after Morgan Stanley cuts rating to underweight

Summary

Event (importance: low). Key entities: Morgan Stanley reiterates Viking Therapeutics. KB match (other): "The best photos from NASA's first moon mission in ". Affected sectors: general. Primary variables: equity_valuations, investor_sentiment, interest_rates. Causal chain: Morgan Stanley reiterates rating based on trial progress → reduces perceived clinical risk for VKTX → may lead to modest upward price pressure on VKTX shares.

Market Impact

Key variables: Viking Therapeutics equity valuation, biotech sector sentiment

Affected sectors: biotechnology, pharmaceuticals